Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Experts Discuss the Evolution of CAR T-Cell Therapy in Multiple Myeloma
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 5, 2022 Expiration: August 4, 2023
Start Activity
Provided by Clinical Care Options LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Jesús G. Berdeja, MD
Sagar Lonial, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discover the similarities and differences among currently available and emerging CAR T-cell therapies in multiple myeloma
  • Identify patients who are likely to benefit from CAR T-cell therapy or are eligible for clinical trial enrollment
  • Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of multiple myeloma
  • Manage toxicities associated with CAR T-cell therapy using available guidelines and online clinical resources and tools and implement strategies to educate patients eligible for this treatment about the potential for these complications

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Jesús G. Berdeja, MD

Director of Multiple Myeloma Research
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Jesús G. Berdeja, MD: consultant: Bluebird, Bristol Myers Squibb, Celgene, CRISPR, Janssen, Kite, Legend, Secura Bio, Takeda; researcher: 2Seventy Bio, AbbVie, Acetylon, Bluebird, Bristol Myers Squibb, C4 Therapeutics, CARsgen, Cartesian, Celgene, Celularity, CRISPR, EMD Serono, Fate, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Karyopharm, Lilly, Novartis, Poseida, Sanofi, Takeda, Teva, Zentalis.
Sagar Lonial, MD

Professor and Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Sagar Lonial, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, Takeda; researcher: Bristol Myers Squibb, Janssen, Novartis, Takeda; stocks: TG Therapeutics.

Staff

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Justine Stanley

Editorial Contributor

Justine Stanley, MSc, has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The goal of this program is to improve the knowledge and competence of learners in integrating CAR T-cell therapy into treatment plans for patients with hematologic malignancies.

Goal

The goal of this program is to improve the knowledge and competence of learners in integrating CAR T-cell therapy into treatment plans for patients with hematologic malignancies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category I Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 05, 2022, through August 04, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Experts Discuss the Evolution of CAR T-Cell Therapy in Multiple Myeloma
  • CME

Loading...
In this on-demand webcast from a live webinar, oncology experts discuss the latest evidence on approved and investigational CAR T-cell therapies for the treatment of multiple myeloma.
Jesús G. Berdeja, MD
Sagar Lonial, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 5, 2022 Expiration: August 4, 2023

Related Content

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

Download these expert-selected slides on anti-BCMA CAR T-cell and bispecific agents for relapsed/refractory myeloma, from Clinical Care Options (CCO).

Noopur Raje, MD Released: September 22, 2022

Download these expert-selected slides on later-stage relapsed/refractory myeloma to help manage your patients, from Clinical Care Options (CCO).

Paul G. Richardson, MD Released: September 22, 2022

See key clinical insights fast, with this short slideset from CCO on relapsed/refractory myeloma, from Clinical Care Options (CCO).

Natalie S. Callander, MD Noopur Raje, MD Paul G. Richardson, MD Released: September 22, 2022
Provided by Clinical Care Options LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings